Advances in the diagnosis and management of lymphoma

摘要: Correspondence: Matthew J Matasar Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Tel +1 212 639 8889 Fax 646 422 2291 Email matasarm@mskcc.org Abstract: The lymphomas are a heterogeneous group of cancers that have played prominent role in the history oncology, being among first to respond radiotherapy or systemic chemotherapy. Progressive improvement understanding biology and natural these diseases has led changes both classification management. Because heterogeneity present lymphomas, accurate diagnosis staging essential prerequisites their effective Lymphoma stage frequently informs treatment decisions, but contrast with solid tumor malignancies carries limited prognostic value. This development models lymphoma, which use patient disease characteristics stratify patients by risk. Modern approaches Hodgkin’s lymphoma include chemotherapy only, combined-modality therapy radiotherapy, risk-adapted modify based on initial response. Management non-Hodgkin’s (NHL) varies widely depending upon histology. Use rituximab, anti-CD20 monoclonal antibody, is included management most B cell improved outcomes diseases. T less common generally well understood than diseases, only recently become disease-specific. Though available for many types relapse remains number subtypes, relapsed refractory remain research priorities.